CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.93% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 89.06M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 89.06M.
Fairly Valued
The company’s latest PE is -12.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.90M shares, decreasing 4.88% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 505.35K shares of this stock.